- KR₩38tn
- KR₩39tn
- KR₩2tn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 35.04 | ||
| PEG Ratio (f) | 0.55 | ||
| EPS Growth (f) | 173.3% | ||
| Dividend Yield (f) | 0.28% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.23 | ||
| Price to Tang. Book | 10.3 | ||
| Price to Free Cashflow | 90.18 | ||
| Price to Sales | 13.11 | ||
| EV to EBITDA | 53.49 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.8% | ||
| Return on Equity | 1.76% | ||
| Operating Margin | 10.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 1,128,459.88 | 1,849,115.53 | 1,893,401.22 | 2,283,967.48 | 2,176,431.53 | 3,501,302 | 4,528,223 | 17.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +24.9 | +67.96 | +19.12 | -9.14 | -2.71 | -45.9 | +173.3 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Directors
- Jeong Jin Seo CHM (63)
- Sin Jae Jang PRE (58)
- Wu Seong Gi CEO (59)
- Sang Jun Lee SVP (54)
- Jeong Won Yoon SVP (54)
- Hyeok Jae Lee MDR (46)
- Min Cheol Shin MDR (50)
- Gi Seong Gwon MDR (52)
- Javier Camposano OTH (59)
- Yun Mo Gu OTH (51)
- Seok Hwan Kang OTH (49)
- Bon Jung Kim OTH (45)
- Ho Seop Lee OTH (46)
- Su Yeong Lee OTH (49)
- Gyeong Ha Shin OTH (48)
- Keith Watson OTH (51)
- Hyeon Ju Yang OTH (50)
- Seong Wuk Yang OTH (51)
- Jin Seok Seo DRC (37)
- Geun Yeong Kim NID (61)
- Won Seok Kim NID (56)
- Jae Sik Lee NID (62)
- Sun Wu Lee NID (69)
- Dae Hyeon Yoo NID (61)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- February 27th, 1991
- Public Since
- July 19th, 2005
- No. of Employees
- 1,074
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 202,635,518
- Address
- 23, Academy-ro, Yeonsu-gu, INCHEON, 22014
- Web
- https://www.celltrion.com/
- Phone
- +82 216618722
- Auditors
- Samil Accounting Corp.
Upcoming Events for 068270
Q1 2025 Celltrion Inc Earnings Release
Q2 2025 Celltrion Inc Earnings Release
Similar to 068270
Gene One Life Science
Korea Exchange - KSE
Orient Bio
Korea Exchange - KSE
FAQ
What is the Celltrion share price?
As of Today at 24:49 UTC, shares in Celltrion are trading at KR₩186,100. This share price information is delayed by 15 minutes.
How has the Celltrion share price performed this year?
Shares in Celltrion last closed at KR₩186,100 and the price had moved by +8.92% over the past 365 days. In terms of relative price strength the Celltrion share price has outperformed the FTSE Developed Asia Pacific Index by +15.12% over the past year.
What are the analyst and broker recommendations for Celltrion?
The overall consensus recommendation for Celltrion is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Celltrion dividend yield?
The Celltrion dividend yield is 0.26% based on the trailing twelve month period.
Does Celltrion pay a dividend?
Last year, Celltrion paid a total dividend of KR₩476, and it currently has a trailing dividend yield of 0.26%.Looking ahead, the next dividend pay date is 2025-04-01.
When does Celltrion next pay dividends?
We do not have data on when Celltrion is to next pay dividends. The historic dividend yield on Celltrion shares is currently 0.26%.
How do I buy Celltrion shares?
To buy shares in Celltrion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Celltrion?
As of the previous close price of KR₩186,100, shares in Celltrion had a market capitalisation of KR₩38tn.
Where are Celltrion shares listed?
Here are the trading details for Celltrion:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 068270
What kind of share is Celltrion?
Based on an overall assessment of its quality, value and momentum Celltrion is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Celltrion share price forecast for 2025?
The analyst consensus target price for shares in Celltrion is KR₩240,896. That is 29.44% above the last closing price of KR₩186,100.
Analysts covering Celltrion currently have a consensus Earnings Per Share (EPS) forecast of KR₩1,943 for the next financial year.
Find out moreWhat is the trend in the Celltrion share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celltrion. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +7.26%.
As of the last closing price of KR₩186,100, shares in Celltrion were trading +3.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Celltrion PE Ratio?
The Celltrion PE ratio based on its reported earnings over the past 12 months is 35.04. The shares last closed at KR₩186,100.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Celltrion?
Celltrion's management team is headed by:
- Jeong Jin Seo - CHM
- Sin Jae Jang - PRE
- Wu Seong Gi - CEO
- Sang Jun Lee - SVP
- Jeong Won Yoon - SVP
- Hyeok Jae Lee - MDR
- Min Cheol Shin - MDR
- Gi Seong Gwon - MDR
- Javier Camposano - OTH
- Yun Mo Gu - OTH
- Seok Hwan Kang - OTH
- Bon Jung Kim - OTH
- Ho Seop Lee - OTH
- Su Yeong Lee - OTH
- Gyeong Ha Shin - OTH
- Keith Watson - OTH
- Hyeon Ju Yang - OTH
- Seong Wuk Yang - OTH
- Jin Seok Seo - DRC
- Geun Yeong Kim - NID
- Won Seok Kim - NID
- Jae Sik Lee - NID
- Sun Wu Lee - NID
- Dae Hyeon Yoo - NID